: Release of a capital market information

Fresenius Medical Care AG: Share buyback

Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014

Share buyback – Interim Report

In the period from July 6, 2026 to July 10, 2026 (each inclusive), 275,500 shares were bought back within the framework of the first tranche of the share buyback of Fresenius Medical Care AG, the start of which was disclosed on May 28, 2026, pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No. 596/2014, Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.

Shares were bought back as follows:

Date	Acquired shares (number)	Weighted average price (in EUR)	Transaction volume (in EUR)	Trading venue
6 July 2026	30,000	41.3110	1,239,330.00	XETR
7 July 2026	7,500	42.0245	315,183.75	XETR
8 July 2026	75,000	41.7833	3,133,747.50	XETR
9 July 2026	80,000	41.8347	3,346,776.00	XETR
10 July 2026	83,000	42.0342	3,488,838.60	XETR

A total of 2,958,040 shares has been acquired within the framework of the first tranche of the share buyback.

The purchase of the shares is carried out by a credit institution commissioned by Fresenius Medical Care AG.

Fresenius Medical Care AG will provide regular information regarding the progress of the share buyback, including by posting its required disclosures at https://freseniusmedicalcare.com/en/investors/shares/share-buyback/.